Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03780257 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene
A Phase 1 study, sponsored by ProQR Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03780257 is a Phase 1 study that has completed, run by ProQR Therapeutics. The registered enrollment target is 20 participants.
The verdict
NCT03780257, a Phase 1 study, has completed, sponsored by ProQR Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of QR-421a administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.
Interventions
- DRUG QR-421a
- OTHER Sham-procedure (dose cohort 1&2 only)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-03-06 |
| Est. Completion | 2021-10-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03780257
The ClinicalTrials.gov registry entry for NCT03780257 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ProQR Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which QR-421a is the first listed.
NCT03780257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03780257 about?
NCT03780257 is a clinical study titled "Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene". The purpose of this study is to evaluate the safety and tolerability of QR-421a administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.
What is the current status of trial NCT03780257?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2019-03-06. Estimated completion is 2021-10-14.
What interventions are being tested in trial NCT03780257?
The interventions under investigation include: QR-421a (DRUG), Sham-procedure (dose cohort 1&2 only) (OTHER).
Who is sponsoring clinical trial NCT03780257?
This trial is sponsored by ProQR Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.